Effect of Grape Seed Proanthocyanidins on Tumor Vasculogenic Mimicry in Liver Cancer Xenograft Mode
Yunyan,Luan,Hongwei,Xiao Xue,Lijian,Bo Zhang,Ruyong,Xin Yao,Hongsheng,Anchi Yu
2014-01-01
Abstract:Objective: As a novel blood supply pattern, vasculogenic mimicry (VM) has attracted increasingly attention in recent years, which may partly compensate for the absence of feeding and facilitate tumor perfusion. However, anti-angiogenic drugs have little effect on VM. The grape seed proanthocyanidins (GSPs), a kind of promising bioactive phytochemical, has shown anti-carcinogenesis and anti-angiogenic in several tumor models. However, GSPs regulation of VM and its possible mechanisms in a H22 hepatoma carcinoma model remain not clear. The aim of this study was to examine the effects of GSPs on proliferation and VM in a H22 hepatoma carcinoma model and to investigate the underlying mechanism. Methods: Seventy-five mice were divided into the control group and experimental groups treated with different concentration of GSPs. CD34-PAS dual staining was employed to identify the VM structure. The immunohistochemical staining for investigating the expression of VEGF, EphA2 and MMP-2 protein was performed. Results: Treatment of the H22 model with Endostar (4 mg/kg), 50, 100, 200 mg/kg of the GSPs resulted in 6.87%, 17.81%, 27.43%, 53.52% inhibition in tumor growth, respectively. The mean weight of tumors were significantly lower in GSPs (100 mg/kg) and GSPs (200 mg/kg) groups than in the control group (all P < 0.01). Similarly, compared with the control group, the number of VM channels were significantly reduced in GSPs (100 mg/kg) and GSPs (200 mg/kg) groups (all P < 0.01). Immunohistochemistry showed significant decreases in the expression levels of VEGF, EphA2 and MMP-2 protein in GSPs (100 mg/kg) and GSPs (200 mg/kg) groups when compared with control group (all P < 0.001). Conclusion: This is the first report providing evidence that GSPs inhibit the VM structure by regulation of the VEGF/EphA2/MMPs signaling pathway. Therefore, we concluded that GSPs has the potential of being a clinical anti-VM inhibitor.